Apellis Pharmaceuticals I... (APLS)
29.14
1.45 (5.24%)
At close: Jan 15, 2025, 11:53 AM
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
| Net Income | -528.63M | -652.17M | -746.35M | -344.87M | -304.71M | -127.50M | -51.01M | -27.12M | -46.52M | -10.79M | -3.96M |
| Depreciation & Amortization | 1.70M | 1.49M | 1.49M | 637.00K | 239.68K | n/a | 11.94K | n/a | n/a | 6.59K | 6.26K |
| Stock-Based Compensation | 105.94M | 91.08M | 70.67M | 45.38M | 21.14M | 7.73M | 5.42M | 1.08M | 545.70K | 659.15K | 271.84K |
| Other Working Capital | -200.34M | 32.63M | -77.59M | 19.64M | 54.79M | -18.63M | -2.12M | -27.21K | -1.10M | -222.65K | 18.88K |
| Other Non-Cash Items | 26.41M | 61.55M | 6.33M | 15.76M | 2.70M | 568.33K | 13.56K | 1.01M | 26.49M | 804.00 | 271.84K |
| Deferred Income Tax | n/a | n/a | 198.26M | 103.03M | 16.34M | n/a | 153.69K | n/a | n/a | n/a | -271.84K |
| Change in Working Capital | -200.17M | -15.70M | -93.52M | 19.59M | 53.15M | -12.04M | -1.19M | 42.57K | 628.31K | 175.01K | 238.81K |
| Operating Cash Flow | -594.74M | -513.75M | -563.13M | -160.49M | -211.14M | -131.24M | -46.60M | -26.00M | -18.86M | -9.95M | -3.44M |
| Capital Expenditures | -773.00K | -1.52M | -1.10M | -5.42M | -1.69M | n/a | n/a | n/a | n/a | -19.95K | n/a |
| Acquisitions | n/a | -61.42M | -248.72M | 311.57M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | n/a | -331.86M | -171.28M | -879.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | n/a | 393.28M | 420.00M | 567.50M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | 99.00K | 61.42M | 248.72M | -311.57M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Investing Cash Flow | -674.00K | 59.89M | 247.62M | -316.99M | -1.69M | n/a | n/a | n/a | n/a | -19.95K | n/a |
| Debt Repayment | n/a | n/a | n/a | 322.87M | 184.21M | n/a | 26.36M | n/a | n/a | n/a | -274.55K |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 10.11M | -14.46M | 11.87M | 369.30M | 204.33M | 709.36K | 20.95M | 14.86M | 41.23M | 18.83M | 7.44M |
| Financial Cash Flow | 394.50M | 365.66M | 392.24M | 692.18M | 388.54M | 131.90M | 197.38M | 14.86M | 41.24M | 18.83M | 7.16M |
| Net Cash Flow | -200.78M | -88.68M | 74.71M | 215.06M | 175.72M | 624.14K | 150.78M | -11.14M | 22.38M | 8.86M | 3.72M |
| Free Cash Flow | -595.51M | -515.27M | -564.23M | -165.91M | -212.83M | -131.24M | -46.60M | -26.00M | -18.86M | -9.97M | -3.44M |